Ampio Reports Positive Results in Early Trial for IV Ampion treatment in COVID-19 Patients

  • Ampion-treated patients showed improvement from severe disease/hospitalization to uninfected/ambulatory on the ordinal scale
  • Ampion-treated patients showed greater improvement compared to patients treated with the standard of care including anti-viral therapies
  • Ampion found to be safe and well-tolerated with no drug related adverse events

Find our more here.

Categories: Ecosystem News